BioCentury
ARTICLE | Clinical News

Ziopharm reports Phase I OS data for Ad-RTS-hIL-12 in GBM

June 9, 2017 7:50 PM UTC

Ziopharm Oncology Inc. (NASDAQ:ZIOP) reported data from 15 evaluable patients with recurrent or progressive glioblastoma multiforme (GBM) or grade III/IV malignant glioma in a Phase I trial showing that a single intratumoral injection of Ad-RTS-hIL-12 (Ad-IL-12; ZIN ATI-001) plus a once-daily 20 mg oral dose of the activator ligand veledimex for 15 doses led to a median overall survival (OS) of 12.5 months. Data were presented at the American Society of Clinical Oncology meeting in Chicago.

The primary endpoint of the open-label, U.S. trial is safety. Secondary endpoints include maximum tolerated dose (MTD) of veledimex, pharmacokinetics, immunogenicity, objective response rate (ORR), progression-free survival (PFS) and OS...